Understanding The Immune Mechanisms Leading To Resolution Of Peanut Allergy
Funder
National Health and Medical Research Council
Funding Amount
$602,472.00
Summary
Food allergy affects up to 10% of children and rates are rising. The greatest rise has been in peanut allergy which is the commonest cause of life threatening reactions. Currently, there is no cure for food allergy. Management relies on food avoidance which is impossible to achieve. Recent deaths in children from food allergy highlight the need for an effective treatment. This project will examine what happens when you grow out of peanut allergy. New information will lead to possible cures.
Probiotic Prawn Oral Immunotherapy (ProPIT) For Treatment Of Prawn Allergy
Funder
National Health and Medical Research Council
Funding Amount
$1,865,369.00
Summary
A ‘curative’ food allergy treatment is needed to prevent deaths and improve care. We recently showed that probiotic peanut oral immunotherapy (PPOIT) was highly effective for treating peanut allergy. 82% of PPOIT treated children gained tolerance compared to 4% of the placebo group. We will now test the combined probiotic-food OIT approach for treating prawn allergy. If successful, we will have identified the first treatment for prawn allergy and a platform treatment for other food allergies.
Maternal Diet Rich In Eggs And Peanuts To Reduce Food Allergies: A Randomised Controlled Trial.
Funder
National Health and Medical Research Council
Funding Amount
$3,719,516.00
Summary
Food allergies now affect more than 1 in every 10 children. Recently, babies have been found to be at risk of developing a food allergy even before they start eating solid foods. We have discovered that baby immune responses can be improved by mothers eating more eggs during the first weeks of breastfeeding. Thus we are undertaking this research trial to determine whether mothers regularly eating more eggs and peanuts during pregnancy and breastfeeding will reduce food allergies in their babies.
Regulation Of Skin Inflammation By Mechanosensor YAP
Funder
National Health and Medical Research Council
Funding Amount
$612,566.00
Summary
Atopic diseases are a significant public health burden in the developed world. The economic cost of care and reduced quality of life for asthmatics necessitates that greater action and resources be directed toward the treatment and prevention of the atopic march. This project aims to identify molecular regulators of this disease process which may identify novel targets for therapy and early intervention.
Methylation-sensitive T Cell Genes And Childhood Food Allergy.
Funder
National Health and Medical Research Council
Funding Amount
$461,232.00
Summary
Australia has the highest reported prevalence food allergy in the world. Despite this, little is known about how allergy develops. Mounting evidence implicates environmentally induced disruption of the genetic blueprint via a process known as epigenetics. We are combining the strengths of food challenge proven food allergy with assessment of immune functioning & cutting edge genomics, to extensively characterise the pathways leading to food allergy in children.
S100 Proteins: Novel Oxidant Scavengers In Allergic Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$505,814.00
Summary
Allergic inflammation includes conditions such as dermatitis and asthma. Asthma, affects one in 10 adults and one in 6 Australians, costing ~$720 million/annum. We will characterize new mediators of oxidant defence which have suppressive effects on key pathogenic processes. The novel oxidative changes in S100 proteins may lead to new diagnostic reagents and new strategies for therapy. Results will open new frontiers in asthma biology and will apply to other chronic inflammatory diseases.
The Regulation Of IgE Antibody Production By Antigen-specific B Cells
Funder
National Health and Medical Research Council
Funding Amount
$454,105.00
Summary
Asthma and other allergies are caused by the inappropriate production of IgE antibodies by the immune system. IgE is not produced in response to most infections but the controls that normally prevent IgE production are unknown. We have identified two separate molecules that prevent IgE production during immune responses. In this proposal we aim to investigate how these controls work. This information may help to devise strategies for controlling IgE production and therefore allergic disease.
Diet And The Gut Microbiota As The Basis For Food Allergies
Funder
National Health and Medical Research Council
Funding Amount
$669,091.00
Summary
Diet and the composition of the gut microbiota represent new avenues to prevent or treat human diseases. We propose that allergies in western countries result from altered gut homeostasis. This application seeks to understand all the molecules involved, and to discover new bacteria that associate with, or protect from allergies.
Dietary Modulation Of Maternal Gut Flora With Oligosaccharides In Pregnancy As A Novel Allergy Prevention Strategy
Funder
National Health and Medical Research Council
Funding Amount
$1,681,512.00
Summary
Declining intake of dietary fibre is a major factor implicated in the changing profile of healthy gut bacteria, and the associated increase in many inflammatory diseases including childhood allergy. This clinical trial aims to confirm findings in animal studies that increased dietary fibre in pregnancy can prevent allergy in the offspring, by favourably influencing metabolism and immune function during pregnancy.
Phase I/IIa Trials Of A Novel T-cell Epitope-based Peptide Therapy For Peanut Allergy
Funder
National Health and Medical Research Council
Funding Amount
$1,440,000.00
Summary
Peanut allergy affects ~2% of the population and is the major cause of food triggered deaths from anaphylaxis. Typically peanut allergy is lifelong. Currently there is no specific treatment. Our vast experience in immunology for house dust mite and grass immunotherapy allowed us to identify critical components of peanut proteins needed as a safe vaccine to build tolerance to peanut foods. Now we will progress this novel and revolutionary vaccine through early phase clinical trials.